Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of GSK Biologicals' dTpa-IPV Vaccine (Boostrix Polio) as a Booster Dose in 3 and 4-year-old Children

NCT01245049 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01245049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01245049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of GSK Biologicals' dTpa-IPV Vaccine (Boostrix Polio) as a Booster Dose in 3 and 4-year-old Children
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
April 1, 2011
Completion date
April 2, 2012
Enrollment
387 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

acellular pertussis, diphtheria, poliomyelitis, tetanus